MedPath

Denenicokin

Generic Name
Denenicokin
Drug Type
Biotech
CAS Number
716840-32-3
Unique Ingredient Identifier
A4LY1V9F0H
Background

Denenicokin is under investigation in clinical trial NCT01152788 (Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma).

Clinical Trials
Related News

FDA Approves ORLYNVAH™: First New Oral Treatment for Uncomplicated UTIs in 25 Years

• Iterum Therapeutics receives FDA approval for ORLYNVAH™, marking the first branded uncomplicated UTI treatment to enter the U.S. market in over 25 years and the first oral penem antibiotic approved in the country. • The drug demonstrates significant potential against multi-drug resistant pathogens, specifically targeting Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis in adult women with limited treatment options. • Iterum reports $24.1 million in cash reserves as of December 2024, with funding projected to sustain operations into the second half of 2025 while pursuing pre-commercialization activities.

Itolizumab Shows Promising Results in Phase 2 Ulcerative Colitis Trial, Matching Adalimumab Efficacy

• Itolizumab demonstrated a 23.3% clinical remission rate in moderate to severe ulcerative colitis patients after 12 weeks, comparable to adalimumab's 20.0% and superior to placebo's 10.0%. • The novel CD6-ALCAM pathway targeting drug achieved 16.7% endoscopic remission, matching adalimumab's performance while maintaining a favorable safety profile. • The Phase 2 trial involved 90 biologic-naïve patients, with itolizumab showing efficacy despite having more severe cases in its treatment arm compared to control groups.

Werewolf Therapeutics Announces 2025 Milestones for IL-2 and IL-12 INDUKINE Programs

• Werewolf Therapeutics anticipates sharing preliminary monotherapy data for WTX-124 in H1 2025, potentially guiding regulatory engagement for accelerated approval. • A Phase 1/2 clinical trial of WTX-330, an IL-12 INDUKINE molecule, is expected to begin in Q1 2025, targeting immunotherapy-resistant cancers. • Interim data from combination expansion arms of WTX-124 with pembrolizumab are expected in Q4 2025, further evaluating its efficacy in solid tumors. • Werewolf's cash position is expected to fund operations through at least the second quarter of 2026, supporting ongoing clinical development.

Vivtex and Equillium Collaborate on Oral Biologic for GI Inflammation

• Vivtex and Equillium have entered a research agreement to develop an oral formulation of EQ302, a bispecific peptide therapy targeting IL-15 and IL-21. • Vivtex will apply its GI-ORIS™ technology to enhance the oral bioavailability of EQ302 for treating gastrointestinal inflammation. • Equillium plans to initiate a Phase 1 clinical trial of the oral EQ302 formulation in the second half of 2025. • The collaboration aims to provide a more convenient and effective treatment option for patients with inflammatory bowel disease and other GI disorders.

Allogeneic NK Cell Therapy Shows Promise in Relapsed Neuroblastoma: Phase I Trial Results

• A Phase I clinical trial evaluated the safety and efficacy of allogeneic natural killer (NK) cell therapy in children with relapsed or refractory neuroblastoma. • The study demonstrated that NK cell therapy is safe and feasible, with no dose-limiting toxicities observed across the tested dose range. • Preliminary efficacy signals were observed, including stable disease in some patients, warranting further investigation in larger trials. • This approach offers a potential new treatment option for high-risk neuroblastoma, addressing the need for more effective therapies.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy